微针针灸治疗干眼症:随机假针刺对照试验方案
本研究为单中心、随机、假针刺对照试验,计划纳入129例干眼症患者,随机分为微针组、假针刺组和人工泪液组,治疗4周并随访至第10周。主要结局为客观症状评分表(OSSS),次要结局包括中国干眼问卷、眼表疾病指数、泪膜破裂时间等。试验已获伦理批准并注册(ChiCTR2300078187)。
要点
- 微针针灸不刺破皮肤,可能成为干眼症的新型治疗选择。
- 试验采用假针刺对照和人工泪液对照,评价微针的疗效与安全性。
- 主要结局为OSSS,次要结局涵盖症状问卷和泪膜稳定性指标。
核心结论
- 微针针灸治疗干眼症的疗效与有效性尚需临床随机对照试验验证。
研究设计与样本
- 单中心、随机、假针刺对照临床试验,计划招募129例干眼症患者,随机分为微针组、假针刺组和人工泪液组,治疗4周,随访至第10周。
- 试验已在上海中医药大学附属市中医医院伦理委员会审查批准(批准号2023SHL-KY-101-01),并在中国临床试验注册中心注册(ChiCTR2300078187)。
关键数值与推荐
- 主要结局为客观症状评分表(OSSS),次要结局包括中国干眼问卷(CDEQ)、眼表疾病指数(OSDI)、非侵入性泪膜破裂时间(NIBUT)、Schirmer试验I(SIT)、泪河高度(TMH)和角膜荧光素染色(CFS)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dry Eye Disease (DED) is a prevalent and significant condition that affects a large number of people. Artificial tears can alleviate the symptoms in patients with mild to moderate dry eyes, but they do not have a long-term effect. Micro-needle is a novel type of acupuncture, with needle tips arrayed on a silicon chip attached to medical plaster, without penetrating the skin. Its effectiveness and efficacy need to be proven clinically. METHODS AND ANALYSIS: This is a single-center, randomized, sham-controlled trial. In total, 129 DED patients will be recruited and randomized into three groups: micro-needle, sham, and artificial tears. They will receive four weeks of treatment and undergo follow-up at six and ten weeks. The primary outcome is measured by the Objective Symptoms Scoring Sheet (OSSS). Secondary outcomes include the China Dry Eye Questionnaire (CDEQ), Ocular Surface Disease Index (OSDI), non-invasive tear film break-up time (NIBUT), Schirmer Test I (SIT), Tear Meniscus Height (TMH), and Corneal Fluorescein Staining (CFS). Questionnaires, including OSSS, CDEQ, and OSDI, will be administered at screening, at the end of week two, and at the conclusion of week four, when treatment is completed. They will also be conducted at follow-up in week six and week ten; OSSS will be taken additionally on day two of the treatment. Tests of Intraocular Pressure (IOP), Best Corrected Visual Acuity (BCVA), NIBUT, SIT 1, TMH, and CFS are conducted at screening and upon completion of treatment. At week two, NIBUT, SIT 1, TMH, and CFS tests are taken as intermittent measurements. ETHICS AND DISSEMINATION: The trial protocol and informed consent document were reviewed and approved by the Ethics Committee of the Shanghai Municipal Hospital of Traditional Chinese Medicine (Approval Number: 2023SHL-KY-101-01). Prior to enrollment, each potential participant undergoes a structured informed consent process conducted by a trained research coordinator, which includes explaining the trial purpose, design, interventions, benefits, risks, and time commitments; providing sufficient time for participants to review the plain-language written informed consent document; addressing all questions to ensure comprehension; and obtaining signed written consent, with a copy provided to the participant and the original stored in the trial file. To safeguard participant confidentiality, all data are labeled with a unique study ID instead of personal identifiers; paper records are stored in locked cabinets in a restricted-access office, and electronic data are stored on password-protected, encrypted servers accessible only to authorized team members via unique logins; de-identified data are used solely for analysis and reporting, with personal identifiers accessible only to the trial coordinator for enrollment and follow-up and never shared with other parties; and study findings in publications and presentations will be aggregated to prevent individual identification. The findings of this investigation will be disseminated through peer-reviewed publications, and any protocol amendments will be submitted to the ethics committee for re-approval and updated in the trial registry. TRIAL REGISTRATION NUMBER: ChiCTR2300078187 TRIAL REGISTRATION DATE: 2023.11.30 TRIAL REGISTRY: China Clinical Trial Registration Center https://www.chictr.org.cn.
引用
- Sun M, Li G, Xu S, et al. Acupuncture with micro-needle for dry eye disease: A study protocol for a randomized, sham-controlled, clinical trial. Complement Ther Med. 2025. PMID: 41093022. doi:10.1016/j.ctim.2025.103265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。